Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.
Did you mean: ➙ act date of cell?

Mediar Therapeutics partners with Lilly to develop a first-in-class WISP1 antibody for idiopathic pulmonary fibrosis

Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, announced a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a...

Axio BioPharma Partners with eMBR Genomics to Manufacture and Distribute Proprietary MKLP1 Pro™ Antibodies

In a milestone for cellular research, eMBR Genomics and Axio BioPharma announce the first commercial availability of MKLP1 Pro™ antibodies, KIF23 gene – the same tools used by the world's leading Midbody Remnants (MBRs) researchers. This strategic...

To advance the first oral therapy for BK Polyomavirus, Orthogon Therapeutics closes an oversubscribed $5.2M financing

Orthogon Therapeutics, a developer of novel antiviral medicines, announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M. This funding will accelerate the development of its...

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Achieved in November...

Great Bay Bio launches its Intelligent Drug Development Ecosystem

On October 18th, the new product launch event hosted by Great Bay Bio (hereinafter referred to as "GBB") was successfully held in Suzhou, where industry players gathered to celebrate the feast of technological innovation. At the event, GBB...

Bruker has acquired Dynamic Biosensors, a pioneer in single-cell interaction cytometry systems, aimed at enhancing drug discovery efforts

Bruker Corporation announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich, Germany. This acquisition strengthens Bruker’s biophysical portfolio for...

ChromaDex expands its pharmaceutical-grade Niagen® IV and injection offerings to more leading wellness clinics.

ChromaDex Corp. the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to announce the second wave of intravenous (IV) wellness clinics that will offer pharmaceutical-grade Niagen®...

Solu Therapeutics appoints Sergio Santillana, MD, as Chief Medical Officer to strengthen its leadership team.

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the appointment of Sergio Santillana, MD, MSc, MBA, as Chief Medical...

The Muscular Dystrophy Association and Forge Biologics announce AAV development

Forge Biologics, a member of Ajinomoto Bio-Pharma Services and leading manufacturer of genetic medicines, today announced it will be the adeno-associated virus (AAV) development and manufacturing partner for the Muscular Dystrophy Association’s...

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

Ibex Medical Analytics (Ibex), the leader in artificial intelligence (AI)-powered cancer diagnostics, announced major advancements in customer growth, validation through a Quest Diagnostics study, regulatory approvals and expansion of its Board of...

Mediar Therapeutics launches a second clinical program targeting fibrosis with novel first-in-class antibodies

Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, today announced the first cohort of participants has been dosed in a Phase 1 trial...

Eximia Research Network expands into Virginia by integrating Tidewater Clinical Research

Eximia Research announces the integration of Tidewater Clinical Research into its national network of clinical trial sites. This strategic development unites Tidewater's longstanding expertise in Women's Health and Ophthalmology with Eximia's...

Transposon announces Phase 2 results for TPN-101 in treating C9orf72-related ALS and frontotemporal dementia

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's disease, announced final results from its Phase...

Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors

Cytoki Pharma, ApS (Cytoki), a clinical-stage biotechnology company pioneering a new class of medicines that harness IL-22 biology to drive improved outcomes for metabolic disease, announced positive data from a Phase 1 study evaluating the...

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center

ViroCell Biologics a cell and gene therapy (“CGT”) contract development and manufacturing organization (“CDMO”) specializing in GMP viral vector manufacturing for clinical trials, announces the signing of a five-year Master Services Agreement...

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or...

Psilera Welcomes Biopharma Executive Dr. Magali Haas to its Board of Directors

Psilera, a leading biotechnology company developing groundbreaking therapies for hard-to-treat neurological disorders, is pleased to announce the appointment of Magali Haas, M.D., Ph.D., to its esteemed Board of Directors. Dr. Haas brings a wealth...

Evogene and Verb Biotics Enter Collaboration Agreement to Advance Probiotic Innovation

Evogene Ltd. a leading computational biology company targeting to revolutionize life-science product development across multiple market segments, and Verb Biotics LLC. A microbiome health ingredient company whose mission is to improve human...

Trailblazing 3D human liver models yield accurate MASH phenotype

Viscient Biosciences ("Viscient") announced that its scientists, along with collaborators from University of California, San Diego, Sanford-Burnham-Prebys medical research institute, and Salk Institute, have published the first demonstration of a...

Results 61 - 79 of 79